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Public health and environmental profession-
als have generally focused on monitoring the
ambient environment to assess exposures to
the public. To understand exposures and
effects and predict onset or course of disease,
it is also important to look inside the
(human) organism. 
Biomarkers—measurable internal indica-
tors of changes in organisms at the molecular
or cellular level—offer great potential to
understand environmentally mediated disease
and to improve the process of risk assessment.
A valid biomarker could also be considered a
key event linking a specific environmental
exposure to a health outcome. 
A molecular biomarkers paradigm has its
origins in the National Research Council’s
(NRC) 1983 “Red Book,” Risk Assessment in
the Federal Government (1). In 1989, the
NRC published monographs on Biologic
Markers in Pulmonary Toxicology (2) and
Biologic Markers in Reproductive Toxicology
(3) in which biomarkers of exposure, effect,
and susceptibility were discussed as they may
relate to disease. In Figure 1, the exposure-to-
disease paradigm has been drawn to empha-
size the application of biomarkers in assessing
dose, mode-of-action, and disease etiology.
Biomarkers of susceptibility may influence
the magnitude of each sequential element in
the pathway. Biomarkers useful for disease
prevention and intervention may appear any-
where along the pathway. Earlier markers (to
the extent that they are measurable at low
exposure or dose) have the greatest potential
utility to avert disease; later markers are most
closely related to the disease.
Over the last decade the biomarker
model has resulted in considerable research
enterprise and nourished and challenged the
emerging field of molecular epidemiology.
The National Institute of Environmental
Health Sciences (NIEHS) and the U.S.
Environmental Protection Agency (U.S.
EPA), in both their intramural and extra-
mural research programs, have targeted bio-
markers for a greater role in human health
risk assessment and have worked for their
validation in the field and their extension
into the clinical environment. At the same
time, much of the biomarker research has
remained confined to the laboratory, with
the promise of successful applications to
improve public health or mitigate disease
largely unmet.
A biomarker should allow better measure-
ments of exposure or earlier identiﬁcation of
health effects. Biomarkers can provide data
needed for assessing progress in improving the
Nation’s health, such as the Healthy People
2010 objectives (4). In summary, biomarkers
may break open the black box between expo-
sure and disease and show what individual
factors make a difference.
Recognizing their substantial investments
in intramural and extramural research on bio-
markers, the NIEHS and the U.S. EPA held
“Biomarkers: Taking Stock, An EPA/NIEHS
In-House Workshop on Applying Biomarker
Research” on 30–31 August 1999 in Chapel
Hill, North Carolina. Approximately 90 par-
ticipants explored biomarker research through
presentations by invited plenary speakers,
posters on individual research projects, and
breakout discussion groups.
Participants focused on both scientific
and organizational objectives. Scientiﬁcally,
they sought to understand the state of the art
and current applications of biomarkers of
exposure, effect, and susceptibility; to discern
research directions that are likely to make the
promise of usable biomarkers a reality; and to
explore the role of biomarkers in understand-
ing environmentally-induced disease and in
assessing human health risk. Organizational
objectives were to increase communication
among NIEHS and U.S. EPA staff, includ-
ing those involved in clinical studies; to com-
plement the ongoing environmental genome
research at NIEHS and the planned NIEHS
workshops on exposure assessment and envi-
ronmental epidemiology; and to lay the
groundwork for a possible extramural confer-
ence on biomarkers in spring 2001. 
Workshop Discussion Themes
Biomarkers in risk assessment. There is a need
to move toward biologically based risk assess-
ments. Biologically based risk assessments will
refine estimates of dose to relevant targets
through the use of biomarkers of exposure.
They will improve hazard characterization
through the use of biomarkers of response or
effect with mechanistic linkage to end points
of concern. They will strengthen inferences
regarding the shape of dose–response curves
outside the range of observation and identify
targets of opportunity for further study in
potentially sensitive human populations.
Biomarkers of exposure, effect, and suscepti-
bility are intimately linked; conceptually it
may be helpful to pull them apart but in reali-
ty they are integrated. Recognizing this link-
age allows for directly tying biomarkers to
testable hypotheses. This requires creative
study design, most often drawing on
researchers from several disciplines.
The U.S. EPA, in its Proposed Guidelines
for Carcinogen Risk Assessment (5), and more
recently the International Programme for
Chemical Safety, with its generic “Framework
for Risk Assessment” (6), have developed sim-
ilar frameworks for bringing a greater variety
of scientiﬁc information into risk assessment.
The basic framework is applicable to all end
points—cancer as well as noncancer.
In this framework the concepts of mode
of action and key events play central roles.
We must distinguish mode of action from
mechanism of action. Mechanism of action is
deﬁned as the detailed molecular description
of the events involved in the induction of
cancer or other health end points. Mode of
action links key events and sequential
processes, starting with the interaction of an
agent with a cell, through functional and
anatomical changes, and resulting in cancer
or other health end points. Consideration of
mode of action raises three questions: How
does the chemical produce its effect? Are
there mechanistic data to support this
hypothesis? Have other mechanistic hypothe-
ses been considered and rejected?
To show that a postulated mode of action
is operative, it is generally necessary to outline
the sequence of events leading to the toxico-
logic or disease end point and to identify key
events that can be measured, often through
biomarkers. Then it is necessary to weigh the
available information to determine whether
the key events are on the pathway to causality.
A key event is defined as an empirically
observable precursor step that is a necessary
element of the mode of action or is a marker
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Meeting Reportsfor such an element. Examples of key events
include metabolism, receptor–ligand changes,
increased cell growth and organ weight, hor-
mone or other physiologic perturbations,
hyperplasia, and cellular proliferation. 
It is also important to understand the
background for dose–response analyses.
When we estimate risk from exposures we
look at incremental exposures—the impact
of a specific exposure on overall risk.
Therefore, we must know something about
the background level of the chemical to
which the increment added, as well as the
background of similar chemicals that operate
by the same mode of action. Finally, we
must know the background of disease so that
we can understand where we are on the
dose–response curve. This is an area where
biomarkers can be applied quite well.
Clearly, this new framework will require
substantial basic and applied research to pro-
vide the information needed for risk assess-
ment. It also provided a useful construct for
consideration of applications of biomarkers
at the workshop.
Biomarkers of susceptibility. An individ-
ual’s susceptibility to environmentally medi-
ated disease may arise from genetic causes or
from nongenetic factors such as age, disease
state, diet, or dietary supplementation. Most
of the discussion at the workshop centered
on understanding genetic susceptibility. 
Polymorphisms may be markers of sus-
ceptibility. The rapid advances of the
Human Genome and Environmental
Genome projects are generating a long list of
genes and their variants (polymorphisms).
Research is helping us to understand which
genes are perturbed on the pathway to dis-
ease. Many of these genes are quite general in
their function and broadly applicable to the
assessment of susceptibility. Such genes or
groups of genes will, for example, inﬂuence
or control cell differentiation, apoptosis, cell
cycle kinetics, or DNA repair. Receptor-
mediated pathways involving alterations in
signal transduction can inﬂuence a variety of
health outcomes. There is a spectrum of
human genetic variability such that a distrib-
ution of responses to a given exposure can
sometimes be predicted.
New technologies such as microchip
arrays allow researchers to explore patterns of
gene expression. In the face of this burgeon-
ing information and data being gathered in
National Institutes of Health and other data-
bases, the challenge for researchers interested
in environmentally mediated disease or risk
assessment is to understand the functionality
of genetic polymorphisms and to relate this
to disease. We may gain this understanding
in humans, particularly by relating laborato-
ry, clinical, and epidemiologic ﬁndings. To
date, most genetic susceptibility studies have
looked at cancers as an end point, although
research on other diseases such as asthma is
beginning to grow. As our understanding of
functionality grows, so will our need for
understanding of the ethical implications of
our knowledge to individuals and society. 
Biomarkers of exposure. Advancing the
utility of biomarkers of exposure requires a
multidisciplinary effort. Biomarkers of expo-
sure may relate external exposure to internal
dose, provide measurable events in dose–
response assessment, and document expo-
sures in epidemiologic studies and clinical
evaluations. 
Biomarkers that integrate exposures from
different pathways or media, thereby inte-
grating dose, are of great interest, particularly
with regard to mixtures. Microarray technol-
ogy has the potential to identify common
patterns of gene expression thus potentially
conﬁrming exposures even to mixtures, but
studies of functionality of protein products
must also be carried out. 
Biomarkers are of value in site-specific
assessment, such as at Superfund sites.
Clearly biomarkers have value and have been
used in assessing acute exposures and acting
as triggers for action, for example in
responding to accidental mercury or methyl-
parathion exposures. Lead in blood, plasma,
or bone is an excellent biomarker of expo-
sure and potentially of effects. Lead bio-
markers also illustrate a challenge in under-
standing the value of information. If we
measure lead in blood in a small population
of children on or near a site and ﬁnd high
blood lead concentrations, there is clearly
cause for concern and action. If, however,
blood lead concentrations are not elevated
compared to national statistical measures or
a local control group, does this mean that
the site presents no problem and there is no
need to act? In this case questions of both
representativeness of samples and population
statistics become paramount. 
The U.S. EPA National Human Exposure
Assessment Survey (NHEXAS) (7) is one
example of a large exposure-based experimen-
tal design on a community or regional level.
We begin with blood, urine, and breath mea-
surements and then return to look at what
people had been exposed to by measuring the
contents of their drinking water, food, and
ambient air to see whether there are correla-
tions. NHEXAS data are now being analyzed
and should yield informative results. 
We need to take a public health approach
to demonstrate the relationship of biomark-
ers to human disease. Advances in molecular
biology have improved the linkage of bio-
markers of effects with biomarkers of expo-
sure, making a top-down public health
approach more feasible, facilitating attribu-
tion of causality, and providing guidance for
decision-making and intervention. 
Biomarkers of effect. Biomarkers of effect
may be either early events on the direct path-
way to disease or toxic end points or predic-
tors of disease or toxicity outside the direct
pathway, i.e., they covary with the toxic
process or disease (Figure 2).
The challenge is to link biomarkers to
human disease both through human and ani-
mal studies. Some approaches would begin
with exposures or highly exposed populations
and look for biomarkers associated with
effects or disease end points. Others would
look for early biomarkers of the disease itself
and then work backward to look at popula-
tions that have exposures to various agents to
see if the biomarker rises as their exposure
rises. In either case establishing linkage
between exposure and disease is critical. 
For studying biomarkers in a human
population, imaging technologies such as
magnetic resonance or positron emission
tomography are particularly interesting
because they are noninvasive and measure
change at a molecular scale.
Successful use of biomarkers of effect,
and in some cases biomarkers of exposure,
requires knowing what they mean in terms of
health and disease. Most have yet to be vali-
dated for ascertainment of health or disease. 
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Figure 1. Applying biomarkers in assessing dose, mode of action, and disease etiology.
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Figure 2. Biomarkers of effect: on the pathway to
disease?
Exposure Biologic effect
(e.g., DNA adducts)
Early lesion Disease
?Biomarkers in susceptibility evaluation
and disease intervention. Development of
biomarkers for environmental agents should
be based on knowledge of metabolism, prod-
uct formation, and general mechanisms of
action. Validation requires parallel experi-
mental and human studies. 
Figure 3 illustrates a systematic approach
for the validation and application of chemi-
cal-speciﬁc biomarkers to human studies (8).
The two end points for this process are vali-
dated markers of exposure and markers of
risk. The paths to the end points pass
through hazard identification, developing
reliable methodologies for measuring bio-
markers, parallel studies in animals and
exposed humans, and epidemiologic studies
and clinical trials. The approach could be
applied to noncancer end points as well 
to cancer. 
This validation approach has been
applied in exhaustive studies relating a)
exposures to aﬂatoxin B1, b) the etiology of
human hepatocellular carcinoma (HCC),
and c) intervention with oltipraz as a chemo-
preventive agent for HCC (8). Biomarkers
included aflatoxin–albumin adducts in
serum and aflatoxin–mercapturic acid
excreted in urine.
Given the multistage process and long
latency of cancer and other chronic human
diseases, it is likely that relatively few indi-
vidual chemical-specific biomarkers will
prove to be validated risk markers. Rather,
validated risk markers may turn out to be
composites of chemical-specific biomarkers
and other markers, each of which con-
tributes in some quantiﬁable way to deter-
mining overall risk (8).
Biomarkers in epidemiologic studies. The
most frequent applications of biomarkers in
molecular epidemiology have been in the
assessment of exposure (or dose) and suscep-
tibility due to genetic and nongenetic factors. 
A recent study of the developmental
effects of fetal exposure to polycyclic aromatic
hydrocarbons (PAHs) via ambient pollution
illustrates the utility of molecular epidemiolo-
gy in identifying potential etiologic factors in
disease (9). The study was intended to gener-
ate hypotheses for further research in an area
that has proven elusive. To complement and
confirm environmental monitoring and
questionnaire data, investigators used bio-
markers to estimate the individual dose of
toxicants to the fetus.
In the study, PAH–DNA adducts in
leukocytes and plasma cotinine were the bio-
markers measured in umbilical cord blood as
dosimeters of transplacental PAHs and ciga-
rette smoke, respectively. Cotinine, a nicotine
metabolite, is uniquely associated with ciga-
rette smoke and provides a means to ascertain
the relative contribution of smoking to a
parameter such as PAH–DNA adducts and
any observed outcome. 
Researchers have not yet realized a goal
of molecular epidemiology to develop pre-
clinical markers that are linked closely
enough to disease that they are suitable for
screening studies, preventative actions, and
diagnosis. They have vividly demonstrated
the complexity of the multiple factors that
determine among those exposed who will get
the disease and who will not. Batteries of
biomarkers may be needed to characterize
this complexity.
Historically much of the research in mol-
ecular epidemiology has been opportunistic,
driven by what populations were available,
what samples have been collected, what
could be measured in an available sample;
out of that one might develop an hypothesis
to test. This was appropriate in the early
stages of biomarker validation. Our under-
standing of the science supporting molecular
epidemiology has now advanced so that we
are prepared to undertake systematic
approaches such as the validation model.
This will allow us to distinguish a key event
on a causal pathway from simply a statistical
association.
Biomarkers in model development. Risk-
assessment models often depend on interpre-
tation at the level of the individual rather
than the population. Generally, surrogate
markers must be used to represent target tis-
sues. The models facilitate interspecies
extrapolation and investigation of the effects
of lower doses/exposures. The models also
facilitate the integration of epidemiologic
and clinical information, in vivo and in vitro
data, and structure–activity concepts.
There is a need for sharing data at the
individual level. It is difﬁcult to develop and
validate risk assessment models based on the
use of data from the literature that consist
only of means and standard errors. Modelers
need to know what is going on in a variety of
situations at the individual human or animal
level. This is important for both the scien-
tists designing or conducting studies and the
regulatory community trying to apply this
information.
An intended use of the biomarker may be
in the clinical setting, where the focus is on
the individual and there is an opportunity to
gather substantial detailed information.
Frequently, however, the intended use is in
the population setting where exposures are
diverse and information about the exposure
and the population of interest is limited. In
the laboratory setting, where in vitro and ani-
mal studies are the norm, there is a substan-
tial advantage in experimental control.
Factors that inﬂuence interindividual vari-
ation include physiology, exposure, environ-
ment, and genetics. The effects of glutathione
transferase theta polymorphism on the risk
estimates for dichloromethane in humans are
an example of the inﬂuence of genetics (10). 
Recommendations
Research emphases. Based on the discussions
at the workshop, the planning committee
identified the following scientific areas for
emphasis in NIEHS and U.S. EPA programs:
• Conduct more prospective (epidemiologic)
studies linking exposure to disease, espe-
cially noncancer diseases
• Apply new technologies (e.g., microchip
arrays) to develop more incisive markers
• Make better use of animal models to devel-
op and link biomarkers to disease in
humans
• Use Bioinformatics to make sense of exist-
ing data (12)
• Continue efforts to discover genetic basis
of risk factors
• Conduct phenotypic and functional studies
of genetic polymorphisms
• Use genetic susceptibility information to
evaluate risk distributed across populations
• Look for risk factors beyond genetic sus-
ceptibility, including age, nutrition,
lifestyle, and sex 
• Develop mechanistic information to link
external exposure to internal dose, particu-
larly for cumulative or aggregate exposures
• Increase emphasis on interdisciplinary
approaches, including cross-training pro-
grams and research
• Use more biomarkers in exposure and
health initiatives
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Figure 3. Model for validating chemical-specific
biomarkers. Reproduced from Groopman and
Kensler (8) by permission of Oxford University
Press. 
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Enhancing research collaboration.
Enhanced research collaboration in areas
related to biomarkers is a subject of great
interest within the federal government.
Looking at exposure assessment alone, before
the end of 2000:
• The NIEHS will publish its report and rec-
ommendations from the workshop on
“The Role of Human Exposure Assessment
in the Prevention of Environmental
Disease” (11). 
• The U.S. General Accounting Ofﬁce will
issue a report assessing a) the extent to
which federal and state agencies collect or
use human exposure data on potentially
harmful chemicals, including data needed
to identify at-risk populations and b) the
main barriers that hinder further progress
in such efforts.
• The Committee on Environment and
Natural Resources of the President’s Ofﬁce
of Science and Technology Policy will
develop a strategy document for considera-
tion as a ﬁscal year 2002 budget initiative.
This initiative will be interagency and facil-
itate leveraging of resources across several
agencies that have made exposure assess-
ment a priority area. 
Governmental initiatives in research col-
laboration will consider the results of all of
these activities.
As their contribution to these considera-
tions, participants at the biomarkers work-
shop developed speciﬁc ideas to enhance col-
laborations between the U.S. EPA and the
NIEHS (and others) to promote innovative
biomarkers research and application.
Examples of these collaborations include:
• Supporting postdoctoral investigators who
are employed on projects that involve
investigators from both institutions
• Jointly planning intramural and extramural
requests for applications/requests for pro-
posals that will encourage the U.S. EPA
and the NIEHS (and others) to collaborate
on innovative biomarkers research 
• Joining the exposure expertise of the U.S.
EPA and the NIEHS with epidemiologic,
toxicologic, and biomarkers expertise of
both institutions
• Establishing joint NIEHS/U.S. EPA work-
shops, working groups, or seminars on top-
ics of mutual concern, such as epidemio-
logic studies being planned or in progress,
microarray technology, or genotyping
methods
• Using the World-Wide Web creatively
through the NIEHS and the U.S. EPA
home pages or a separate Web site that
could identify ongoing epidemiologic and
toxicologic studies and seminars, or support
interest groups, e-mail list servers, discussion
groups, etc., to stimulate collaborations 
• Looking for speciﬁc opportunities for col-
laboration in existing/developing research
programs, e.g., NHEXAS (7) the National
Cancer Institute/NIEHS/U.S. EPA
Agricultural Health Study (13); the
National Toxicology Program study
design including animal/sample sharing
(14); and site-specific risk assessment
(opportunity to apply biomarkers in the
ﬁeld)
• Sharing resources, especially specialized
equipment, between the two institutions.
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